Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US - Concepedia

Concepedia

Publication | Open Access

Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

DOI Full Paper Access

40

Citations

19

References

2014

Year

Allison Perrin, Steven Sherman, Sumanta K. Pal, Andrew Seng Boon Chua, Magdaliz Gorritz, Zhimei Liu, Xufang Wang, Kenneth W. Culver, Roman Casciano, Louis P. Garrison

Journal of Medical Economics

Abstract

The results suggest that everolimus likely leads to lower lifetime costs than axitinib for sunitinib-refractory advanced RCC patients in the US.

References

	Year	Citations

Page 1